Published in Hepatitis Weekly, September 17th, 2001
The study involves over 300 patients with chronic hepatitis B virus (HBV) infection. SciClone believes the study is currently one of the largest randomized, double-blind clinical trial using Zadaxin to date. This trial is designed with a six-month treatment period followed by a 12-month long evaluation to specifically address the issue of patient relapse which has been seen in other chronic hepatitis B treatments after therapy is stopped.
Measuring the endpoints of HBV DNA...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly